These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31412533)

  • 21. A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of triple-negative breast cancer.
    Wu J; Cai Y; Zhao G; Li M
    J Clin Lab Anal; 2021 Jun; 35(6):e23779. PubMed ID: 33934391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer.
    Ensenyat-Mendez M; Orozco JIJ; Llinàs-Arias P; Íñiguez-Muñoz S; Baker JL; Salomon MP; Martí M; DiNome ML; Cortés J; Marzese DM
    Commun Med (Lond); 2023 Jul; 3(1):93. PubMed ID: 37430006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.
    Liu YR; Jiang YZ; Xu XE; Hu X; Yu KD; Shao ZM
    Clin Cancer Res; 2016 Apr; 22(7):1653-62. PubMed ID: 26813360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease.
    Pinto JA; Araujo J; Cardenas NK; Morante Z; Doimi F; Vidaurre T; Balko JM; Gomez HL
    NPJ Genom Med; 2016; 1():15015. PubMed ID: 29263808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The early-stage triple-negative breast cancer landscape derives a novel prognostic signature and therapeutic target.
    Yang YS; Ren YX; Liu CL; Hao S; Xu XE; Jin X; Jiang YZ; Shao ZM
    Breast Cancer Res Treat; 2022 Jun; 193(2):319-330. PubMed ID: 35334008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
    Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
    Front Immunol; 2021; 12():749459. PubMed ID: 34603338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TTK is a favorable prognostic biomarker for triple-negative breast cancer survival.
    Xu Q; Xu Y; Pan B; Wu L; Ren X; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Zhang X; Wang C; Zhong Y; Zhou L; Liang Z; Zhao H; Sun Q
    Oncotarget; 2016 Dec; 7(49):81815-81829. PubMed ID: 27833085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
    Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
    Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin-like growth factor 2 receptor is a key immune-related gene that is correlated with a poor prognosis in patients with triple-negative breast cancer: A bioinformatics analysis.
    Zhong Y; Ren X; Cao X; Xu Y; Song Y; Zhou Y; Mao F; Shen S; Wang Z; Sun Q
    Front Oncol; 2022; 12():871786. PubMed ID: 36330486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers.
    Moon HG; Oh K; Lee J; Lee M; Kim JY; Yoo TK; Seo MW; Park AK; Ryu HS; Jung EJ; Kim N; Jeong S; Han W; Lee DS; Noh DY
    Breast Cancer Res Treat; 2015 Nov; 154(1):13-22. PubMed ID: 26438141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis.
    Kim EK; Park AK; Ko E; Park WY; Lee KM; Noh DY; Han W
    Breast Cancer Res Treat; 2019 Nov; 178(1):185-197. PubMed ID: 31342312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
    Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
    Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
    Zhang J; Zhang M; Tian Q; Yang J
    Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction and Validation of a Prognostic Risk Model for Triple-Negative Breast Cancer Based on Autophagy-Related Genes.
    Yan C; Liu Q; Jia R
    Front Oncol; 2022; 12():829045. PubMed ID: 35186763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
    Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
    Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor infiltrating CD8
    Mella M; Kauppila JH; Karihtala P; Lehenkari P; Jukkola-Vuorinen A; Soini Y; Auvinen P; Vaarala MH; Ronkainen H; Kauppila S; Haapasaari KM; Vuopala KS; Selander KS
    Oncoimmunology; 2015 Jun; 4(6):e1002726. PubMed ID: 26155410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
    Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
    BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of ERBB4 expression in patients with triple negative breast cancer.
    Kim JY; Jung HH; Do IG; Bae S; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Park YH; Im YH
    BMC Cancer; 2016 Feb; 16():138. PubMed ID: 26907936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
    Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
    Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.